home / stock / aqst / aqst news

AQST News and Press, Aquestive Therapeutics Inc. From 03/25/21

Stock Information
Company Name: Aquestive Therapeutics Inc.
Stock Symbol: AQST
Market: NASDAQ
Website: aquestive.com
Menu
AQST AQST Quote AQST Short AQST News AQST Articles AQST Message Board
Get AQST Alerts

News, Short Squeeze, Breakout and More Instantly...
AQST - Aquestive Therapeutics Successfully Demonstrates Repeatable and Predictable Oral Sublingual Film Administration of Epinephrine

Provides in-depth scientific and clinical data in R&D event today at 9:00 am ET Outlines data from two completed Phase 1 pharmacokinetic (PK) trials for AQST-108 (dipivefrin) sublingual film Articulates development strategy for second prodrug candidate, AQST-109 su...
AQST - Aquestive Therapeutics, Inc. (AQST) Q4 2020 Earnings Call Transcript

Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q4 2020 Earnings Call Mar 10, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Aquestive Therapeutics, Inc. (AQST) Q4 2020 Earnings Call Tran...

AQST - Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2020 Results - Earnings Call Transcript

Aquestive Therapeutics, Inc. (AQST) Q4 2020 Earnings Conference Call March 10, 2021 08:00 ET Company Participants Stephanie Carrington - Investor Relations Keith Kendall - President and Chief Executive Officer Ernie Toth - Interim Chief Financial Officer Daniel Barber - Senior Vice President ...

AQST - Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021 Epinephrine program and development strategy to be highlighted at a virtual investor event to be held at 9:00 a.m. ET on March 25, 2021 Entered U.S. licensing and...
AQST - Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9:00 a.m. ET

WARREN, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will hos...

AQST - Aquestive receives FDA feedback; to resubmit marketing application for Libervant

Aquestive Therapeutics (AQST) announced that it received written feedback from the FDA regarding its New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters.The guidance received from the regulator included the FDA’s expe...

AQST - Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant(TM) (diazepam) Buccal Film Following FDA Feedback

Reaffirms plans to resubmit its New Drug Application (NDA) around the end of second quarter 2021 Received additional feedback from FDA after completion of Type A meeting and submission of revised weight based dosing regimen Anticipates an FDA action date in 2021 ...
AQST - Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8:00 a.m. ET

WARREN, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will repo...

AQST - Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors

WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment o...

AQST - Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy

New hire helps lead Aquestive’s continued focus on its epinephrine program Provides update on Libervant™ (diazepam) Buccal Film WARREN, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused o...
Previous 10 Next 10